// App-Quantinova.ai

15068 : Comparison of Extended-Release Niacin versus Placebo in Statin-Treated Patients With Low Baseline Levels of HDL-C and Well-Controlled on-Treatment LDL-C: Extended One-Year Follow-Up Outcomes From AIM-HIGH

Researchers

Presenter

  • William E Boden

Principal Investigators

  • Ruth McBride

  • Patrice Desvigne-Nickens

  • Jerome Fleg

  • Todd Anderson

  • Moti Kashyap

Medical Centers

  • Axio Res, Seattle, WA

  • The Samuel S. Stratton Albany VA Medical Ctr, Albany, NY

  • Foothills Medcl Ctr, Calgary, AB, Canada

  • NCI/NHLBI, Bethesda, MD

  • Long Beach VA Medical Ctr, Long Beach, CA

  • University of Washington, Seattle, WA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Ischemic stroke

  • Dyslipidemia

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • simvastatin + ezetimibe

  • Niacor

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved